METiS Therapeutics

Founded with a mission to revolutionize drug discovery, METiS Therapeutics leverages cutting-edge technologies to develop novel therapeutics for serious diseases. The company focuses on integrating Artificial Intelligence (AI), Machine Learning (ML), and Molecular Dynamics (MD) to create innovative small molecule drugs, biologics, and advanced nucleic acids. METiS' lead programs utilize AI and high-throughput in vivo screening to discover unique lipid nanoparticles (LNPs) with exceptional targeting capabilities.

Notable figures affiliated with METiS Therapeutics include experts in AI-driven drug discovery and seasoned professionals from the pharmaceutical industry. The company has attracted significant investment from leading venture capital firms, underscoring its potential impact. Key achievements include the development of proprietary LNPs that enhance drug delivery and efficacy. METiS Therapeutics is poised to make a substantial impact on the treatment of serious diseases through its pioneering approach to integrated drug discovery.